Onco, Nucro begin lab work under IND enabling program

Executive Summary

• Nucro-Technics Inc. has initiated laboratory work under its investigational new drug enabling program in collaboration with Onco-Innovations Ltd.
• The primary focus is the development and validation of advanced analytical methods to measure Onco-Innovations' exclusively licensed polynucleotide kinase phosphatase (PNKP) inhibitor in preclinical samples and drug formulations.
• This work establishes essential analytical tools required by regulators as a necessary precondition for advancing the compound into human clinical trials.

Key Details

• Parties Involved: Nucro-Technics Inc. (Toronto-based contract research organization) and Onco-Innovations Ltd.
• Technology Target: Polynucleotide kinase phosphatase (PNKP) inhibitor, also known as A83B4C63.
• Analytical Methodology: Development of liquid chromatography-mass spectrometry (LC-MS) assays, described as a gold standard for sensitive and precise drug measurement.
• Scope of Analysis: The assays are designed to quantify the PNKP technology in animal model plasma, biological systems, and Onco-Innovations' proprietary polymer-based nanoparticle delivery system.
• Specific Capabilities: The methods enable accurate measurement of both free and encapsulated forms of the compound to assess stability, metabolism, and overall drug exposure in vivo.
• Regulatory Context: Validated methods are required by the U.S. Food and Drug Administration (FDA) and Health Canada to ensure safety and dosing data are accurate, reproducible, and suitable for decision-making.
• Future Studies: Once validated, these methods will serve as the foundation for formal toxicology and pharmacokinetic assessments conducted under good laboratory practice (GLP) standards.
• Strategic Goal: The work aims to generate high-quality data to guide formulation optimization and dosing strategies while preparing for regulatory submissions.

Notable Quotes

• "The validated analytical tools Nucro-Technics is now developing are not only essential for our regulatory submissions but also critical for understanding how PNKP technology behaves in the body as we advance a new class of DNA repair-targeting therapies towards the clinic," stated Thomas O'Shaughnessy, chief executive officer of Onco-Innovations.